** Shares of Mineralys Therapeutics MLYS.O down 0.5% at $14.89 early Tues as co looks to raise equity after its stock soared in previous session
** MLYS shares on Mon hit two-year high, before ending session up 42% at $14.96, after its blood pressure drug, lorundrostat, met main goals in mid- and late-stage trials
** After the bell, co commenced $250 mln stock offering to fund development of lorundrostat, as well as working capital, general purposes
** BofA, Evercore, Goldman Sachs, Stifel and Wells Fargo are jt bookrunners
** The Radnor, Pennsylvania-based firm has ~49.8 mln shares outstanding for ~$745 mln market cap
** All 7 analysts covering MLYS are bullish with $33 median PT, LSEG data shows
** Co went public in Feb 2023 IPO priced at $16
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
(( lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。